|1.||Vollmann, Arabel: 1 article (07/2006)|
|2.||Braun, Yvonne: 1 article (07/2006)|
|3.||Kuhnen, Cornelius: 1 article (07/2006)|
|4.||Wai, Daniel H: 1 article (07/2006)|
|5.||Poremba, Christopher: 1 article (07/2006)|
|6.||Schaefer, Karl-Ludwig: 1 article (07/2006)|
|7.||Gabbert, Helmut E: 1 article (07/2006)|
|8.||Brockhoff, Gero: 1 article (07/2006)|
|9.||Brachwitz, Kristin: 1 article (07/2006)|
|10.||Zahn, Susanne: 1 article (07/2006)|
|1.||Pancreatic Neoplasms (Pancreatic Cancer)
10/15/2005 - "Our data also indicated that SU6656 and PD158780 inhibited Akt activation in pancreatic cancer cells by interfering with the ability of IRS-1 to recruit PI3K. "
10/15/2005 - "Consistent with this possibility, PI3K was precipitated with anti-phosphotyrosine antibodies and Akt phosphorylation was blocked by the tyrosine kinase inhibitors SU6656 and PD158780 in quiescent pancreatic cancer cells. "
07/01/2006 - "This difference was not strictly dependent on endogenous NRG1 expression; however, the growth-inhibiting effect of the pan-ErbB tyrosine kinase inhibitor CI-1033 or PD158780 clearly correlated with NRG1 expression indicating an autocrine growth stimulation loop which may constitute an interesting target of new therapeutic strategies in this tumor entity."
|1.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|2.||Neuregulin-1 (Neuregulin 1)
|4.||Epidermal Growth Factor Receptor (EGF Receptor)
|6.||CI1033 (CI 1033)